YU61096A - Novel intermediates, their use in the synthesis of n,n'-bridged bisindolylmaleimides and pharmaceutical formulations - Google Patents
Novel intermediates, their use in the synthesis of n,n'-bridged bisindolylmaleimides and pharmaceutical formulationsInfo
- Publication number
- YU61096A YU61096A YU61096A YU61096A YU61096A YU 61096 A YU61096 A YU 61096A YU 61096 A YU61096 A YU 61096A YU 61096 A YU61096 A YU 61096A YU 61096 A YU61096 A YU 61096A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- pharmaceutical formulations
- synthesis
- novel intermediates
- bridged
- bridged bisindolylmaleimides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Ovaj pronalazak izlaže jedinjenja formule Pronalazak dalje izlaže korišćenje ovog jedinjenja za dobijanje N,N'-premoštenih bisihdolimaleimida. Dalje, ovaj pronalazak izlaže farmaceutske formulacije i postupke za njihovo korišćenje u suzbijanju protein kinaze C kod sisara.The present invention discloses compounds of formula The invention further discloses the use of this compound for the preparation of N, N'-bridged bisihydolimaleimides. Further, the present invention discloses pharmaceutical formulations and methods for their use in suppressing protein kinase C in mammals.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US734595P | 1995-11-20 | 1995-11-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
YU61096A true YU61096A (en) | 1999-03-04 |
YU49316B YU49316B (en) | 2005-06-10 |
Family
ID=21725638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU61096A YU49316B (en) | 1995-11-20 | 1996-11-18 | Novel intermediates, their use to prepare n,n'-bridged bisindolylmaleimides and pharmaceutical formulations |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP0776899B1 (en) |
JP (2) | JP4100708B2 (en) |
KR (1) | KR100342142B1 (en) |
CN (1) | CN1066734C (en) |
AR (2) | AR004719A1 (en) |
AT (1) | ATE191219T1 (en) |
AU (1) | AU701659B2 (en) |
BR (1) | BR9611709A (en) |
CA (1) | CA2237401C (en) |
CO (1) | CO4750824A1 (en) |
CZ (1) | CZ150398A3 (en) |
DE (1) | DE69607443T2 (en) |
DK (1) | DK0776899T3 (en) |
EA (1) | EA000639B1 (en) |
ES (1) | ES2145978T3 (en) |
GR (1) | GR3033729T3 (en) |
HU (1) | HU225716B1 (en) |
IL (1) | IL124415A (en) |
MX (1) | MX9803791A (en) |
MY (1) | MY118946A (en) |
NO (1) | NO310195B1 (en) |
NZ (1) | NZ323282A (en) |
PE (1) | PE17998A1 (en) |
PL (1) | PL184728B1 (en) |
PT (1) | PT776899E (en) |
TR (1) | TR199800876T2 (en) |
TW (1) | TW371661B (en) |
UA (1) | UA56145C2 (en) |
WO (1) | WO1997019080A1 (en) |
YU (1) | YU49316B (en) |
ZA (1) | ZA969645B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1070068B2 (en) * | 1998-03-13 | 2007-01-17 | The University Of British Columbia | Granulatimide derivatives for use in cancer treatment |
CA2245029A1 (en) | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6300106B1 (en) | 2000-11-22 | 2001-10-09 | Ppg Industries Ohio, Inc. | Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate |
EP2181999A1 (en) | 2008-11-03 | 2010-05-05 | Zentiva, A.S. | Method of manufacturing ruboxistarin |
WO2023192984A1 (en) * | 2022-03-31 | 2023-10-05 | 4M Therapeutics Inc. | N-desmethyl ruboxistaurin as kinase inhibitor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
IL94274A0 (en) * | 1989-05-05 | 1991-03-10 | Goedecke Ag | Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
NO308798B1 (en) * | 1993-12-07 | 2000-10-30 | Lilly Co Eli | Protein kinase C inhibitors, use of same for the manufacture of pharmaceuticals and pharmaceutical formulation comprising the same |
US5559228A (en) * | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
-
1996
- 1996-11-18 ZA ZA9609645A patent/ZA969645B/en unknown
- 1996-11-18 YU YU61096A patent/YU49316B/en unknown
- 1996-11-18 JP JP51983897A patent/JP4100708B2/en not_active Expired - Fee Related
- 1996-11-18 CZ CZ981503A patent/CZ150398A3/en unknown
- 1996-11-18 DE DE69607443T patent/DE69607443T2/en not_active Expired - Fee Related
- 1996-11-18 EP EP96308317A patent/EP0776899B1/en not_active Expired - Lifetime
- 1996-11-18 AU AU77388/96A patent/AU701659B2/en not_active Ceased
- 1996-11-18 TR TR1998/00876T patent/TR199800876T2/en unknown
- 1996-11-18 KR KR1019980703626A patent/KR100342142B1/en not_active IP Right Cessation
- 1996-11-18 ES ES96308317T patent/ES2145978T3/en not_active Expired - Lifetime
- 1996-11-18 UA UA98052516A patent/UA56145C2/en unknown
- 1996-11-18 PL PL96326753A patent/PL184728B1/en not_active IP Right Cessation
- 1996-11-18 PT PT96308317T patent/PT776899E/en unknown
- 1996-11-18 CA CA002237401A patent/CA2237401C/en not_active Expired - Fee Related
- 1996-11-18 WO PCT/US1996/018518 patent/WO1997019080A1/en not_active Application Discontinuation
- 1996-11-18 IL IL12441596A patent/IL124415A/en not_active IP Right Cessation
- 1996-11-18 BR BR9611709A patent/BR9611709A/en not_active IP Right Cessation
- 1996-11-18 NZ NZ323282A patent/NZ323282A/en unknown
- 1996-11-18 AT AT96308317T patent/ATE191219T1/en not_active IP Right Cessation
- 1996-11-18 DK DK96308317T patent/DK0776899T3/en active
- 1996-11-18 CN CN96199575A patent/CN1066734C/en not_active Expired - Fee Related
- 1996-11-18 EA EA199800368A patent/EA000639B1/en not_active IP Right Cessation
- 1996-11-18 HU HU9901975A patent/HU225716B1/en not_active IP Right Cessation
- 1996-11-18 PE PE1996000828A patent/PE17998A1/en not_active Application Discontinuation
- 1996-11-18 TW TW085114104A patent/TW371661B/en active
- 1996-11-19 CO CO96060836A patent/CO4750824A1/en unknown
- 1996-11-19 MY MYPI96004798A patent/MY118946A/en unknown
- 1996-11-20 AR ARP960105257A patent/AR004719A1/en unknown
- 1996-11-20 AR ARP960105256A patent/AR004718A1/en unknown
-
1998
- 1998-05-08 NO NO19982105A patent/NO310195B1/en not_active IP Right Cessation
- 1998-05-13 MX MX9803791A patent/MX9803791A/en unknown
-
2000
- 2000-06-20 GR GR20000401423T patent/GR3033729T3/en not_active IP Right Cessation
-
2007
- 2007-12-28 JP JP2007338808A patent/JP2008138006A/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2162843T3 (en) | INHIBITORS OF PROTEIN QUINASA C. | |
TR199800759T2 (en) | Protein Kinase C Inhibitor. | |
MX9707431A (en) | Protein kinase c inhibitors. | |
ES2056699T3 (en) | SUBSTITUTED DIAMINOFTALIMIDES AND ANALOGS. | |
CA2219359A1 (en) | Hydantoin derivatives as intermediates for pharmaceutical active compounds | |
YU61096A (en) | Novel intermediates, their use in the synthesis of n,n'-bridged bisindolylmaleimides and pharmaceutical formulations | |
DE69330601D1 (en) | SEROTON INERGIC ERGOLIN DERIVATIVES | |
MX9303605A (en) | DERIVATIVES OF AZABICICLOHEPTANO N-SUBSTITUTED, ITS OBTAINING AND USE. | |
FI852743A0 (en) | ACETYLENISKA FENOXIPROPANOLDERIVAT OCH PHARMACEUTICAL COMPOSITION FOER BEHANDLING AV HYPERTONI. | |
ECSP961937A (en) | PROTEIN KINASE INHIBITOR "C" |